Delivery Order SPE2DB24D2010-SPE2DB25FAAZN
- Not listed
- The Defense Logistics Agency awarded a $4,540.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 16, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $41,759.43 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is the vendor's...
- The Defense Logistics Agency awarded a delivery order valued at $10,617.27 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with a completion date of June 11, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $4,336.55 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 15, 2025. This non-competitive delivery order represents a firm fixed-price transaction executed under AmerisourceBergen's broader relationship with DLA for pharmaceutical supply. The product is a PCSK9 inhibitor used for cholesterol management, reflecting the company's ongoing role in supplying...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $42,932.71 by the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed price, non-set-aside contract is scheduled for completion by August 20, 2025, and will be fulfilled at the company's Conshohocken facility. The award represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $12,889.99 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award to the pharmaceutical distributor and represents a continuation of the company's ongoing supply relationship with DLA. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,232.28 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 13, 2025. This competitive, firm fixed-price delivery order represents a continuation of pharmaceutical supply under AmerisourceBergen's existing contract vehicle with DLA. The award carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $62,369.85 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 22, 2025. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical...
- The Defense Logistics Agency awarded a $27,040.46 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with a completion date of September 3, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $55,027.37 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 21, 2025. This firm fixed-price contract, awarded on August 20, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAAZNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $19,734.44 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 28, 2025. This competitive award (no set-aside designation) represents a firm fixed-price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle running through December 2026. The product being delivered is a specialty cardiovascular medication used for cholesterol management, continuing AmerisourceBergen's extensive role as a critical pharmaceutical distributor for federal military and healthcare systems. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor providing comprehensive medical supply solutions to federal customers including the Defense Health Agency and U.S. Coast Guard. The company's extensive contract portfolio with the DLA demonstrates its capability to supply a wide range of pharmaceutical products across multiple therapeutic domains through open competition. This delivery order exemplifies the company's ongoing support of military healthcare procurement needs through the DLA's global pharmaceutical supply network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.7k | 8/27/25 |